Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Triple Negative Breast Neoplasms × utomilumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Prostatic Neoplasms 1 Papillomavirus Infections 1 Oropharyngeal Neoplasms 1 Neoplasms 1 Melanoma 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma 1 Lung Neoplasms 1 Liver Neoplasms 1 Kidney Neoplasms 1 Head and Neck Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Advanced/Metastatic Solid Tumors 1

Interventions

pembrolizumab 142 Carboplatin 125 Paclitaxel 108 Cyclophosphamide 77 130-nm albumin-bound paclitaxel 59 Capecitabine 56 Gemcitabine 45 Doxorubicin 44 Albumin-Bound Paclitaxel 37 atezolizumab 36 Taxes 34 Cisplatin 33 Nivolumab 31 sacituzumab govitecan 28 Docetaxel 28 Epirubicin 27 olaparib 26 Specimen Handling 25 eribulin 24 Bevacizumab 24 durvalumab 23 Biopsy 22 camrelizumab 21 Magnetic Resonance Spectroscopy 21 Drug Therapy 21 toripalimab 17 Radiotherapy 14 liposomal doxorubicin 13 Vinorelbine 13 Everolimus 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03971409 2025-05-02

InCITe

University of California, San Francisco

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡